Therapy for fungal diseases: opportunities and priorities

Park, 2009, Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS, Aids, 23, 525, 10.1097/QAD.0b013e328322ffac Agarwal, 2009, Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis, Int. J. Tuberc. Lung Dis., 13, 936 Vicente, 2003, Microbial natural products as a source of antifungals, Clin. Microbiol. Infect., 9, 15, 10.1046/j.1469-0691.2003.00489.x Chain, 1940, Penicillin as a chemotherapeutic agent, Lancet, 236, 226, 10.1016/S0140-6736(01)08728-1 Medoff, G. and Kobayashi, G.A. (1980) The Polyenes in Antifungal Chemotherapy. John Wiley & Sons Donovick, 1955, Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies, Antibiot. Annu., 3, 579 Torrado, 2008, Amphotericin B formulations and drug targeting, J. Pharm. Sci., 97, 2405, 10.1002/jps.21179 Groll, 2003, Comparative drug disposition, urinary pharmacokinetics and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits, Antimicrob. Agents Chemother., 47, 3917, 10.1128/AAC.47.12.3917-3925.2003 Gershkovich, 2009, Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation, J. Antimicrob. Chemother., 64, 101, 10.1093/jac/dkp140 Groll, 2006, Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations, Antimicrob. Agents Chemother., 50, 3418, 10.1128/AAC.00241-06 Wingard, 2000, A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group, Clin. Infect. Dis., 31, 1155, 10.1086/317451 Cornely, 2007, Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial), Clin. Infect. Dis., 44, 1289, 10.1086/514341 Kuse, 2007, Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial, Lancet, 369, 1519, 10.1016/S0140-6736(07)60605-9 Verweij, 2008, In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus, Antimicrob. Agents Chemother., 52, 4483, 10.1128/AAC.00491-08 Vandevelde, 1972, 5-fluorocytosine in the treatment of mycotic infections, Ann. Intern. Med., 77, 43, 10.7326/0003-4819-77-1-43 Hope, W.W. (2010) Flucytosine (5-fluorocytosine; 5FC). In Kucers’ the Use of Antibiotics Normark, 1972, In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata, Antimicrob. Agents Chemother., 2, 114, 10.1128/AAC.2.3.114 Stamm, 1987, Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis, Am. J. Med., 83, 236, 10.1016/0002-9343(87)90691-7 Perfect, J.R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291–322 Fromtling, 1988, Overview of medically important antifungal azole derivatives, Clin. Microbiol. Rev., 1, 187, 10.1128/CMR.1.2.187 McLachlan, 1996, Pharmacokinetics of fluconazole in people with HIV infection: a population analysis, Br. J. Clin. Pharmacol., 41, 291, 10.1046/j.1365-2125.1996.03085.x Rex, 1994, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute, N. Engl. J. Med., 331, 1325, 10.1056/NEJM199411173312001 Slavin, 1995, Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study, J. Infect. Dis., 171, 1545, 10.1093/infdis/171.6.1545 Dastghaib, 2005, Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole, J. Dermatolog. Treat., 16, 43, 10.1080/09546630510025932 Denning, 1989, Treatment of invasive aspergillosis with itraconazole, Am. J. Med., 86, 791, 10.1016/0002-9343(89)90475-0 Barone, 1998, Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers, Pharmacotherapy, 18, 295 Glasmacher, 2003, Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients, J. Clin. Oncol., 21, 4615, 10.1200/JCO.2003.04.052 Zonios, 2008, Update on azole antifungals, Semin. Respir. Crit. Care. Med., 29, 198, 10.1055/s-2008-1063858 Eisen, 2004, Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis, Mycoses, 47, 159, 10.1111/j.1439-0507.2004.00959.x Lestner, 2009, Toxicodynamics of itraconazole: implications for therapeutic drug monitoring, Clin. Infect. Dis., 49, 928, 10.1086/605499 Walsh, 2008, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clin. Infect. Dis., 46, 327, 10.1086/525258 Walsh, 2002, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, N. Engl. J. Med., 346, 225, 10.1056/NEJM200201243460403 Torres, 2005, Posaconazole: a broad-spectrum triazole antifungal, Lancet Infect. Dis., 5, 775, 10.1016/S1473-3099(05)70297-8 Courtney, 2004, Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults, Br. J. Clin. Pharmacol., 57, 218, 10.1046/j.1365-2125.2003.01977.x Courtney, 2004, Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men, Antimicrob. Agents Chemother., 48, 804, 10.1128/AAC.48.3.804-808.2004 Cornely, 2007, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N. Engl. J. Med., 356, 348, 10.1056/NEJMoa061094 Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N. Engl. J. Med., 356, 335, 10.1056/NEJMoa061098 Walsh, 2007, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial, Clin. Infect. Dis., 44, 2, 10.1086/508774 Greenberg, 2006, Posaconazole as salvage therapy for zygomycosis, Antimicrob. Agents Chemother., 50, 126, 10.1128/AAC.50.1.126-133.2006 Petranyi, 1984, Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase, Science, 224, 1239, 10.1126/science.6547247 Sigurgeirsson, 2002, Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study, Arch. Dermatol., 138, 353, 10.1001/archderm.138.3.353 Gosbell, 2003, Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery, Mycoses, 46, 233, 10.1046/j.1439-0507.2003.00878.x Denning, 2003, Echinocandin antifungal drugs, Lancet, 362, 1142, 10.1016/S0140-6736(03)14472-8 Petraitiene, 2002, Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia, Antimicrob. Agents Chemother., 46, 12, 10.1128/AAC.46.1.12-23.2002 Gudlaugsson, 2003, Attributable mortality of nosocomial candidemia, revisited, Clin. Infect. Dis., 37, 1172, 10.1086/378745 Hassan, 2009, Excess mortality, length of stay and cost attributable to candidaemia, J. Infect., 59, 360, 10.1016/j.jinf.2009.08.020 Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N. Engl. J. Med., 356, 2472, 10.1056/NEJMoa066906 Kullberg, 2005, Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial, Lancet, 366, 1435, 10.1016/S0140-6736(05)67490-9 Mora-Duarte, 2002, Comparison of caspofungin and amphotericin B for invasive candidiasis, N. Engl. J. Med., 347, 2020, 10.1056/NEJMoa021585 Garcia-Effron, 2008, A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility, Antimicrob. Agents Chemother., 52, 2305, 10.1128/AAC.00262-08 Pappas, 2007, Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin. Infect. Dis., 45, 883, 10.1086/520980 Park, 2005, Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates, Antimicrob. Agents Chemother., 49, 3264, 10.1128/AAC.49.8.3264-3273.2005 Balashov, 2006, Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1, Antimicrob. Agents Chemother., 50, 2058, 10.1128/AAC.01653-05 Garey, 2006, Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study, Clin. Infect. Dis., 43, 25, 10.1086/504810 Baquir, 2010, Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein, J. Infect. Dis., 201, 473, 10.1086/649901 Kauffman, 2000, Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group, Clin. Infect. Dis., 30, 14, 10.1086/313583 Kobayashi, 2004, Candiduria in hospital patients: a study prospective, Mycopathologia, 158, 49, 10.1023/B:MYCO.0000038436.51918.d9 Hope, 2009, Assessing candiduria in a critically ill patient, Br. Med. J., 338, b2289, 10.1136/bmj.b2289 Tuon, 2009, Bladder irrigation with amphotericin B and fungal urinary tract infection-systematic review with meta-analysis, Int. J. Infect. Dis., 13, 701, 10.1016/j.ijid.2008.10.012 Sobel, 2000, Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group, Clin. Infect. Dis., 30, 19, 10.1086/313580 Lundstrom, 2001, Nosocomial candiduria: a review, Clin. Infect. Dis., 32, 1602, 10.1086/320531 Hamza, 2008, Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial, Clin. Infect. Dis., 47, 1270, 10.1086/592578 Villanueva, 2001, A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis, Clin. Infect. Dis., 33, 1529, 10.1086/323401 de Wet, 2004, A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients, Clin. Infect. Dis., 39, 842, 10.1086/423377 Krause, 2004, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis, Clin. Infect. Dis., 39, 770, 10.1086/423378 Sawyer, 1994, Vulvovaginal candidiasis in young women with cystic fibrosis, Br. Med. J., 308, 1609, 10.1136/bmj.308.6944.1609 Sobel, 2003, Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine, Am. J. Obstet. Gynecol., 189, 1297, 10.1067/S0002-9378(03)00726-9 White, 2001, Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections, Sex Transm. Infect., 77, 212, 10.1136/sti.77.3.212 Moudgal, 2003, Antifungal drugs in pregnancy: a review, Expert Opin. Drug Saf., 2, 475, 10.1517/14740338.2.5.475 Verweij, 2009, Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?, Lancet Infect. Dis., 9, 789, 10.1016/S1473-3099(09)70265-8 Howard, 2009, Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure, Emerg. Infect. Dis., 15, 1068, 10.3201/eid1507.090043 Denning, 1990, Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases, Rev. Infect. Dis., 12, 1147, 10.1093/clinids/12.6.1147 Bates, 2001, Mortality and costs of acute renal failure associated with amphotericin B therapy, Clin. Infect. Dis., 32, 686, 10.1086/319211 Wingard, 1999, Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis, Clin. Infect. Dis., 29, 1402, 10.1086/313498 Ellis, 1998, An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis, Clin. Infect. Dis., 27, 1406, 10.1086/515033 Denning, 1994, NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis, Am. J. Med., 97, 135, 10.1016/0002-9343(94)90023-X Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N. Engl. J. Med., 347, 408, 10.1056/NEJMoa020191 Nivoix, 2008, Factors associated with overall and attributable mortality in invasive aspergillosis, Clin. Infect. Dis., 47, 1176, 10.1086/592255 Upton, 2007, Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality, Clin. Infect. Dis., 44, 531, 10.1086/510592 Wheeler, 2006, A drug-sensitive genetic network masks fungi from the immune system, PLoS Pathog, 2, e35, 10.1371/journal.ppat.0020035 Hohl, 2008, Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure, J. Infect. Dis., 198, 176, 10.1086/589304 Lamaris, 2008, Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae, J. Infect. Dis., 198, 186, 10.1086/589305 Ouchi, 2007, Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin, J. Infect. Chemother., 13, 258, 10.1007/s10156-007-0524-9 Denning, 2003, Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review, Clin. Infect. Dis., 37, S265, 10.1086/376526 Camuset, 2007, Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients, Chest, 131, 1435, 10.1378/chest.06-2441 Crosdale, 2001, Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis, J. Infect. Dis., 184, 653, 10.1086/322791 Sambatakou, 2006, Cytokine profiling of pulmonary aspergillosis, Int. J. Immunogenet., 33, 297, 10.1111/j.1744-313X.2006.00616.x Vaid, 2007, Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis, Clin. Chem. Lab. Med., 45, 183, 10.1515/CCLM.2007.033 Jain, 2006, The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis, J. Infect., 52, e133, 10.1016/j.jinf.2005.08.022 Snelders, 2008, Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism, PLoS Med., 5, e219, 10.1371/journal.pmed.0050219 Stevens, 2000, A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis, N. Engl. J. Med., 342, 756, 10.1056/NEJM200003163421102 Wark, 2003, Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial, J. Allergy Clin. Immunol., 111, 952, 10.1067/mai.2003.1388 Denning, 2009, Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study, Am. J. Respir. Crit. Care Med., 179, 11, 10.1164/rccm.200805-737OC Longley, 2008, Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda, Clin. Infect. Dis., 47, 1556, 10.1086/593194 Nussbaum, 2010, Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi, Clin. Infect. Dis., 50, 338, 10.1086/649861 Roden, 2005, Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin. Infect. Dis., 41, 634, 10.1086/432579 Kontoyiannis, 2005, Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases, J. Infect. Dis., 191, 1350, 10.1086/428780 Reed, 2008, Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis, Clin. Infect. Dis., 47, 364, 10.1086/589857 Spellberg, 2009, Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis, Antimicrob. Agents Chemother., 53, 3122, 10.1128/AAC.00361-09 Ben-Ami, 2009, Phaeohyphomycosis in a tertiary care cancer center, Clin. Infect. Dis., 48, 1033, 10.1086/597400